<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

IN DEVELOPMENT

Trusted partner in lung disease

Our vision is to be the trusted partner that the world relies on for data-driven answers in lung disease and beyond.

We consistently engage with our customers, key opinion leaders, and scientific experts to identify additional clinical unmet needs related to diagnosis, treatment and monitoring in lung disease where a diagnostic test could help improve patient care.

Our lung focused diagnostic tests in development

Treatment Guidance

EARLY STAGE LUNG CANCER
Can a blood test identify a subgroup of early stage NSCLC patients who have a high risk of recurrence post-curative resection and may benefit from adjuvant therapy?


LATE STAGE LUNG CANCER
Can a blood test identify patients who may benefit from single agent or combination immune checkpoint inhibitors, independent of currently approved biomarkers?

 

Monitoring

EARLY STAGE LUNG CANCER
Can a blood test detect minimal residual disease from molecular markers in the blood?


LATE STAGE LUNG CANCER
Can a blood test detect dynamic molecular changes that indicate whether a patient is responding to ongoing treatment with targeted therapies?

Get in touch

Contact us

Data library

Discover more